Senior Director, Clinical Dosimetry & Radiation Sciences

Your Impact Alpha-9 Oncology is seeking a Medical Physicist to lead clinical dosimetry and quantitative imaging across our radiopharmaceutical clinical programs. Reporting into Clinical Development, this role serves as the internal scientific lead for dosimetry methodology and imaging quantification, ensuring rigor, consistency, and interpretability across multiple active studies. You will define and own how clinical dosimetry is performed at Alpha-9 and ensure it is fully integrated into trial design, dose escalation strategy, and regulatory decision-making. This role operates at the intersection of clinical development, clinical pharmacology, regulatory affairs, and external imaging partners, with direct influence on how quantitative radiopharmaceutical data is translated into clinical decisions. How You’ll Contribute Lead clinical dosimetry strategy across Alpha-9’s radiopharmaceutical programs, defining standards for absorbed dose calculation, time-activity modeling, and interpretation across early-phase clinical studies. Establish and govern quantitative imaging standards for SPECT/CT and PET/CT, including acquisition protocols, reconstruction parameters, QC frameworks, and site qualification criteria. Serve as the internal authority on dosimetry, translating patient- and program-level dose data into actionable insights that inform dose escalation, safety evaluation, and clinical decision-making. Integrate dosimetry into clinical trial design and regulatory submissions, including protocols, amendments, investigator brochures, clinical study reports, and IND/CTA documentation. Partner closely with Clinical Development, Clinical Pharmacology, Biostatistics, and Clinical Operations to ensure dosimetry is embedded in dose selection strategy and study execution. Manage external imaging and dosimetry vendors and core laboratories, ensuring methodological consistency, data quality, and timely delivery across active programs. Support regulatory interactions and scientific communications, including responses to agencies, investigator meetings, abstracts, manuscripts, and conference presentations. The Skills You Bring PhD or MS in Medical Physics, Radiation Physics, Nuclear Medicine Physics, or related discipline (Ph.D. preferred). 6–10+ years of experience in radiopharmaceutical development, molecular imaging, or medical physics within oncology drug development. Direct experience in radiopharmaceutical or radioligand therapy clinical programs required. Proven experience with quantitative SPECT/CT and PET/CT imaging workflows in clinical trial settings. Strong understanding of internal dosimetry principles (e.g., MIRD methodology) and organ/tumor absorbed dose modeling. Experience contributing to or supporting IND/CTA submissions and regulatory interactions involving imaging or dosimetry. Demonstrated ability to translate quantitative radiopharmaceutical data into clinical development decisions. Experience operating in cross-functional drug development teams, ideally across multiple concurrent clinical programs. Experience influencing or contributing to dosimetry methodology, standards, or decision frameworks in clinical development preferred. Board certification (ABR or equivalent) preferred. Company Summary Alpha-9 Oncology is a clinical-stage biotechnology company pioneering radiopharmaceutical innovation for solid tumors. Our proprietary scaffolds, composed of optimized binders, linkers, chelators, and radioisotopes, enable targeted radiation delivery to cancer cells, minimizing harm to surrounding healthy tissue. Focusing on innovative targeting moieties, we develop molecules tailored for precise tumor targeting. Our comprehensive platform integrates imaging and therapeutic studies to ensure effective radiation delivery and improved patient outcomes. With a robust pipeline entering clinical trials and strong support from leading healthcare investors, Alpha-9 is positioned for rapid growth and advancement in cancer therapy. Mor